J. Alan Crunkleton, PhD, MD
President, CEO, Director
Alan Crunkleton has led Correx since cofounding the company in 2004. His background combines medical training with 15 years of entrepreneurial experience and 30 years in both academic and commercial research and development. With this background, Dr. Crunkleton contributes a unique understanding of both the market and the technologies under development, enabling effective communication in both arenas to meet goals and objectives for commercialization and clinical adoption.
Prior to his position at Correx, Dr. Crunkleton cofounded Boreas, Inc., a venture capital-backed, cryogenic refrigeration company, serving as President and CEO. He earned a medical degree at the University of Massachusetts Medical School in 2002. Dr. Crunkleton holds M.S. and Ph.D. degrees in mechanical engineering from the Massachusetts Institute of Technology (MIT). He holds several patents, medical and nonmedical. Dr. Crunkleton is a coauthor of the patent for the Correx 18 MM AVB Kit.
Joel B. Braunstein, MD, MBA, FACC
Dr. Joel Braunstein is a cofounder and managing partner of LifeTech Development Partners, a lead investor in Correx. He is also cofounder and CEO of LifeTech Research, a life sciences investment research firm formed in 2003; cofounder and Chairman of Centegen, Inc.; cofounder and board member of C2N Diagnostics; and board member of Nexgen Medical Systems and Tivorsan Pharmaceuticals.
Dr. Braunstein is a board certified cardiologist and internist. In his clinical capacity, Dr. Braunstein is affiliated with Yale University School of Medicine and the Yale Center for Outcomes Research and Evaluations.